KGL Resources (ASX:KGL) has received the green light to build its wholly owned Jervois Copper Project in the Northern Territory following a final investment decision. Since its last interview with The Stock Network in August, KGL has received the full early deposit from Wheaton Precious Metals, joined the All Ordinaries Index and appointed a new independent director. CEO Sam Strohmayr joins The Stock Network’s @LelSmits to discuss the construction timeline, Jervois processing plant and the pathway to first copper. 🏗️ Moving Jervois into construction ⚙️ Building the processing plant ⛏️ Advancing towards first copper Watch the full interview ⚡youtube.com/watch?v=QtqoOZFA… @KGLResources $KGL

Alcidion (ASX:ALC) Managing Director and CEO Kate Quirke is speaking at the @TIPGroup_Ltd Conference, discussing the expansion of its Miya Precision healthcare software platform across hospitals in the UK, Australia and New Zealand, following a record financial year with revenue up 27% and positive operating cash flow. With an expanded contract secured with Northern Care Alliance NHS Foundation Trust, Kate joins The Stock Network’s @LelSmits to explore upgrading existing hospital customers, competing for hospital contracts and Alcidion’s growth outlook. TSN Interview: 🏥 Upgrading existing hospital customers to Miya Flow 🇦🇺 Competing for NHS and Australian hospital contracts ⚡ Watch the full interview: youtube.com/watch?v=PXSe2dK8… Register for TIP's conference: 🗓️ Wednesday 21 October 2026 📍 The Glass House, Melbourne 👉 tipgroup.com.au/tip-conferen… @alcidion $ALC

Cogstate CEO and Managing Director Brad O’Connor is speaking at the @TIPGroup_Ltd Conference, discussing the company’s cognitive testing technology supporting clinical trials across Alzheimer’s disease, sleep, rare disease and psychiatry. Following a record year, Cogstate is supporting more trials than ever while returning capital through dividends and a share buy-back. Brad joins The Stock Network’s @LelSmits to discuss recent bipolar and depression trial wins, clinical technology partnerships and the role of AI in improving trial operations. TSN Interview: 🧠 Landing late-stage bipolar and depression trials through clinical technology partnerships 🤖 Using AI and automation to improve clinical trial operations ⚡ Watch the full interview: youtube.com/watch?v=_dF_KmKb… Register for TIP’s conference: 🗓️ Wednesday 21 October 2026 📍 The Glass House, Melbourne 👉 tipgroup.com.au/tip-conferen… @Cogstate $CGS

How much of your everyday life runs on a company you’ve probably never heard of? For a lot of Aussies, that’s @Glencore (ASX:GLC). It’s the biggest producer of coal, cobalt, nickel, lead and zinc in Australia. The Swiss company has just started trading on the ASX, but its main listing stays in London, with another in Johannesburg. And the pitch to Aussie investors? Copper. Glencore says it has a clear path to becoming one of the world’s biggest producers. But its coal and trading businesses are bringing in the cash right now. Here’s TSN’s Take. A new listing is a sales pitch, so look past the growth story and check what's actually paying the bills today. #mining #Copper #ASX #Investing #stocks

Tasmea Managing Director Stephen Young is speaking at the @TIPGroup_Ltd Conference, discussing the group’s record FY26 result, upgraded FY27 earnings guidance and growing opportunities across data centres, resources and energy. Following the completion of the Maxim and JPS acquisitions and the build-up of a record order book, Stephen joins The Stock Network’s @LelSmits to explore Tasmea’s growth strategy, electrification demand and the outlook for the year ahead. TSN Interview: 🏗️ Building a high-return growth platform ⚡ Data centres: Maximising a major growth opportunity ⛏️ Resources and energy: The core earnings engine 🚀 Entrepreneurial growth, disciplined risk 👉 Watch the full interview: youtube.com/watch?v=3JiIDbur… Register for TIP's conference: 🗓️ Wednesday 21 October 2026 📍 The Glass House, Melbourne 👉 tipgroup.com.au/tip-conferen… #tasmealimited $TEA

ECS Botanics Managing Director Nan-Maree Schoerie is speaking at the @TIPGroup_Ltd Conference, discussing the company’s transition to positive EBITDA and operating cash flow in FY26 as branded sales doubled. Following its launch in Germany, ECS has secured a supply agreement with Curaleaf Laboratories to expand into the UK medicinal cannabis market. Nan-Maree joins The Stock Network’s @LelSmits to discuss production cost reductions, international expansion and opportunities across the UK and Europe. TSN Interview: 🌱 Cutting ECS Botanics' cost of growing medicinal cannabis 🌍 Taking Australian-grown medicinal cannabis into the UK and Europe ⚡ Watch the full interview: youtube.com/watch?v=DU0ytKpB… Register for TIP's conference: 🗓️ Wednesday 21 October 2026 📍 The Glass House, Melbourne 👉 tipgroup.com.au/tip-conferen… @BotanicsEcs $ECS

Starpharma (ASX: SPL, US OTC: SPHRY) has secured majority ownership of Petalion Therapeutics, strengthening its targeted oncology portfolio and taking operational leadership of a differentiated cancer therapy program. ⚕️ Increased its stake in Petalion Therapeutics from 22.5% to 66%, with Medicxi remaining a strategic partner 🔬 Expanding oncology capabilities through Petalion's FAP-targeted dendrimer-drug conjugate program 🎯 Advancing drug development with a focus on lead candidate selection and defining the next development pathway "Petalion is strongly aligned with our strategy to build a focused portfolio of differentiated targeted-oncology therapies. Its FAP-targeted dendrimer-drug conjugate complements our broader work in targeted drug delivery and demonstrates the versatility of the DEP® platform across therapeutic payloads." Cheryl Maley, CEO ASX announcement ⚡ asx.api.cmfyapp.com/asx-rese… @Starpharma_ASX $SPL

Centuria Capital Group Co-Head of Unlisted Funds Stuart Wilton is speaking at the @TIPGroup_Ltd Conference, discussing the group’s $22.2 billion asset portfolio and its latest unlisted property fund, seeded with a prime Sydney CBD office asset. With more than 15,000 private investors across its unlisted property funds, Stuart joins The Stock Network’s @LelSmits to explore what private investors want from property, selecting assets for unlisted funds and the outlook for the sector. TSN Interview: 🏢 Backing larger single-asset Centuria property funds 📈 Shaping the outlook for Centuria's unlisted property funds ⚡ Watch the full interview: youtube.com/watch?v=k-0hb_Cn… Register for TIP's conference: 🗓️ Wednesday 21 October 2026 📍 The Glass House, Melbourne 👉 tipgroup.com.au/tip-conferen… @CenturiaCapital $CNI

EBR Systems (ASX: EBR) is taking its wireless cardiac pacing technology to the global stage, with its WiSE System set to feature in multiple scientific sessions at APHRS 2026 in Busan, South Korea, from 21–24 October. 🇺🇸 Presentations will include real-world data from the first 100 US commercial implants. 🫀 Researchers will explore leadless left ventricular pacing and its potential role in cardiac resynchronisation therapy. 👨‍⚕️ Expert sessions will share strategies to optimise procedural success with the WiSE System. "APHRS 2026 provides an important opportunity to share our growing commercial experience with the WiSE® System and explore its potential to expand pacing options for patients." John McCutcheon, President & CEO ASX announcement ⚡ asx.api.cmfyapp.com/asx-rese… @EBRSystemsInc $EBR

Europa Metals has listed on the ASX with the ticker code of EUZ. The company is a Europe-focused antimony and gold explorer. It has the right to acquire five exploration blocks located along a circa 40km trend within the north-western Tethyan Metallogenic Belt in Austria’s eastern Alps. The three priority projects within these blocks, the Kreuzeck West, Kreuzeck East and Goldeck-Siflitz projects, host documented historic production of both high-grade antimony and gold. They also come with additional copper, nickel and cobalt potential, and boast underground access and strong supporting datasets. Board of Directors: Executive Chairman - Myles Campion; Executive Director (proposed) - Executive Director & CEO - Torey Marshall; Non‑Executive Director - Dr Evan Kirby Senior Management: Company Secretary - Daniel Smith Media: The Stock Network, Lel Smits

Acrux (ASX:ACR) is progressing its Female Testosterone metered-dose transdermal spray, with the FDA confirming the Phase III clinical development pathway for treating Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women. 🔬 The company is finalising protocols for two 24-week Phase III trials to assess efficacy, alongside additional safety data collection. 🇺🇸 FDA guidance confirms Acrux will be eligible to apply for a three-year exclusivity period upon submission for approval. 🤝 The regulatory clarity is supporting co-development discussions with potential partners as Acrux advances its clinical strategy. "Our confidence is supported by the ongoing income stream from our commercialised Topical Generic Portfolio in US and the Research and Development Tax Incentive rebate (RDTI). It is also supported by the realignment of our cost base to focus on Female Testosterone MDTS.” John Warmbrunn, CEO ASX announcement ⚡ asx.api.cmfyapp.com/asx-rese… #acrux $ACR

Rivco Australia Executive Manager - Corporate Lachlan Campbell is speaking at the @TIPGroup_Ltd Conference, discussing the company’s Australian water entitlement portfolio across the southern Murray-Darling Basin and its growing relationships with farmers. Since bringing management in-house last November, Rivco has increased the share of its portfolio leased to farmers from approximately 50 per cent to 80 per cent. Lachlan joins The Stock Network’s @LelSmits to discuss positioning Rivco’s portfolio where Murray water supply is tightest, securing long-term tenants among Australia’s largest irrigators and the water challenges facing California. TSN Interview: 💧 Positioning Rivco’s water portfolio where Murray supply is tightest 🌱 Securing long-term tenants among Australia’s largest irrigators 🇺🇲 Exploring water challenges in California ⚡ Watch the full interview: youtube.com/watch?v=kwyrKnAs… Register for TIP's conference: 🗓️ Wednesday 21 October 2026 📍The Glass House, Melbourne 👉 tipgroup.com.au/tip-conferen… #rivcoaustralia $RIV

Far East Gold (ASX:FEG) is defending its board and flagship Idenburg gold project ahead of next Wednesday’s shareholder vote, following a push by its largest shareholder, Xingye, to remove four directors. Managing Director and CEO Shane Menere joins The Stock Network’s Izaac Ronay to address Xingye’s claims and explain what’s at stake in the vote. 🪓 Holding management accountable or seeking control 📈 Delivering for Far East Gold shareholders 🤝 Losing the strategic investor relationship 🌏 Weighing Xingye’s Hong Kong listing plans ⛏️ Progressing asset sales 🏗️ Addressing governance and the right to change the board ⚒️ Finding a commercial solution with Xingye ⛰️ Taking the message to shareholders Watch the full interview ⚡ youtube.com/watch?v=cGMeLTvI… @FEG_LTD $FEG

Solvar CEO and Managing Director Scott Baldwin is speaking at the @TIPGroup_Ltd Conference, discussing the group’s Australian loan book, which has surpassed $1 billion for the first time, and its more than $400 million in funding headroom to support growth across consumer and commercial lending. Scott joins The Stock Network’s @LelSmits to discuss loan book momentum, maintaining credit quality and growing Bennji as a second engine of commercial lending growth. TSN Interview: 📈 Building on loan book growth in FY27 🛡️ Managing credit quality across Solvar’s loan book 🚀 Bennji becoming a second growth engine ⚡ Watch the full interview: youtube.com/watch?v=qYKFf7BO… Register for TIP's conference: 🗓️ Wednesday 21 October 2026 📍The Glass House, Melbourne 👉 tipgroup.com.au/tip-conferen…

Overwatch Technologies has listed on the ASX with a ticker code of OWL. The company uses drone-based platforms and sensors to detect, map and track radio-frequency emissions. Its intelligence, surveillance and reconnaissance services support government clients monitoring maritime threats, including illegal fishing, trafficking and dark fleets. Overwatch plans to expand into land and subsea data capture while building a high-margin dataset monetisation business. Board of Directors: Executive Chairman - Harry Karelis; Managing Director and Chief Executive Officer - Oscar Leslie; Independent Non-Executive Director - Michael Outram; Non-Executive Director - Nathan Munn Senior Management: Chief Technology Officer - Stuart Reed; Co-founder and Advisory Board Member - Niv Karmi; Strategic Adviser - Anthony (Tony) Bamford; Chief Financial Officer (external) and Company Secretary - Mindy Ku Media: The Stock Network, Lel Smits

EBR Systems (ASX:EBR) has appointed Dr Robert Canby as Chief Medical Officer, strengthening its clinical leadership as the company advances US commercial adoption and continued clinical development of its WiSE System. 🩺 Dr Canby brings extensive experience in cardiac electrophysiology, cardiovascular research and medical devices. 🚀 He will lead EBR’s medical and clinical strategy, supporting evidence development and physician engagement. 🫀 EBR’s WiSE System stimulates the heart’s left ventricle without a conventional coronary sinus pacing lead. “I am excited to take on the role of EBR Systems’ CMO. I have always been interested in the intersection of technology and better clinical outcomes for our patients." Dr. Robert Canby, Chief Medical Officer "Dr. Canby is a highly respected cardiac electrophysiologist and brings an exceptional combination of clinical expertise, medical device experience and a deep understanding of cardiac electrophysiology." John McCutcheon, President & CEO ASX announcement⚡ asx.api.cmfyapp.com/asx-rese… @EBRSystemsInc $EBR

Noxopharm (ASX:NOX) is taking its lupus drug candidate SOF-SKN™ from a completed Phase I trial towards patients, with its proprietary Sofra™ technology platform opening up further therapeutic areas. The company has just released its 2026 Annual Report. 🔬 Completing a Phase I trial of SOF-SKN™, its topical treatment candidate for cutaneous lupus, which demonstrated safety and tolerability in healthy volunteers. 🚀 Preparing an extension study to evaluate SOF-SKN™ in cutaneous lupus patients, ahead of a potential Phase II trial. 🧪 Expanding the Sofra™ platform across autoimmune diseases, chronic inflammation, immuno-oncology and RNA therapeutics. "To all our shareholders, I would like to say thank you for your support, and for entrusting me with the next stage of Noxopharm's growth." - CEO, Dr Olivier Laczka Annual report ⚡️ asx.api.cmfyapp.com/asx-rese… @noxopharm $NOX